Home / Conditions / Chronic Hepatitis B
Chronic Hepatitis B: when insurers say no, reviewers often say yes
In 14 published external-review decisions involving chronic hepatitis b, independent physician reviewers overturned the insurer’s denial 78.6% of the time.
Published decisions
14
2001–2026
Overturned
78.6%
11 denials reversed
Most-fought treatments for chronic hepatitis b
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Vemlidy | 11 | 81.8% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 11 | 81.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 66.7% |
Typical time to a decision
10 days
Most land between 7 and 21 days
Handled as urgent
7.1%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for a liver fibrosis test. FibroTest (liver fibrosis test) has demonstrated that it reliably determines the presence of advanced fibrosis and cirrhosis in a variety of liver diseases, including hepatitis B. Liver biopsy, by contrast, is invasive, with risks including bleeding and bile duct injury. It is also subject to interoperator variability during interpretation and sampling error. The American Association for the Study of Liver Diseases guidelines for hepatitis B characterize FibroTest as valid for the assessment of liver fibrosis and cirrhosis, and recommend assessment of fibrosis in the diagnostic criteria to characterize hepatitis B and differentiate chronic hepatitis B from immune-tolerant, immune-active, and inactive hepatitis B.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for apolipoprotein testing as a component of a NASH FibroSURE test panel. Medical literatures note that chronic hepatitis B may result in complications of severe liver disease and in cirrhosis. Medical literatures explain that cirrhosis is the final outcome of all chronic liver disease, and that management of cirrhosis requires specific therapy and monitoring for complications such as hepatocellular carcinoma surveillance with ultrasound and alpha-fetoprotein every six months, and monitoring for portal hypertension, esophageal varices, and hepatic encephalopathy. Researchers report that fibrosis blood tests have been validated in chronic hepatitis C and that the diagnostic performance of blood tests in hepatitis B.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for a liver fibrosis test. According to the medical records, the patient has chronic hepatitis B. Current American Association for the Study of Liver Diseases and American Gastroenterological Association guidelines recommend transient elastography as the preferred noninvasive modality for fibrosis assessment in chronic hepatitis B.Transient elastography demonstrates superior diagnostic accuracy for advanced fibrosis and cirrhosis in patients with chronic hepatitis B compared with serum-based liver fibrosis testing.
The patient is requesting authorization and coverage for Vemlidy 25 mg tablets.Findings: Guidelines recommend entecavir and tenofovir for the treatment of chronic hepatitis B. In comparison with tenofovir disoproxil fumarate (Viread), the Vemlidy formulation of tenofovir is effective for hepatitis B, but is associated with fewer incidence of side effects such as osteopenia and renal disease. However, the other guidelines also support the safety and efficacy of entecavir for the treatment of hepatitis B, and entecavir is not associated with these adverse effects. This patient does not have a documented contraindication to entecavir.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for chronic hepatitis b was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.